Apellis Pharmaceuticals Inc
(NAS:APLS)
$
28.075
-0.485 (-1.7%)
Market Cap: 3.49 Bil
Enterprise Value: 3.59 Bil
PE Ratio: 0
PB Ratio: 12.94
GF Score: 42/100 Apellis Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020 / 12:20PM GMT
Release Date Price:
$30.34
(+1.71%)
Lut Ming Cheng
BofA Merrill Lynch, Research Division - Associate
Good morning. I'm Brian Cheng. I'm the associate on (inaudible) Mid-Cap Biotech team here at Bank of America. Thanks for joining us at the fireside chat this morning with
(technical difficulty)
Joining from Apellis this morning is CEO, Cedric Francois; CFO, Tim Sullivan; and CCO, Adam Townsend. Good morning, guys.
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Hi, Brian. Thank you for having us.
Lut Ming Cheng
BofA Merrill Lynch, Research Division - Associate
So before we get to questions about your indications, Cedric, why don't you go ahead and briefly highlight your company's achievement so far and the upcoming catalyst for the investor this year?
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Thank you so much, Brian. So for those on the call that don't know our company well, we are a biotech
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot